Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (SMA)

PMLiVE USA

Overview

Biogen’s investigational antisense oligonucleotide (ASO), salanersen, has received FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (SMA). This designation is based on early clinical data showing improved motor function and slowed neurodegeneration in pediatric SMA patients who did not achieve optimal outcomes with existing therapies. Salanersen potentially offers high efficacy with once-yearly dosing, expected to reduce administration frequency compared to current SMA treatments.

In Depth

Key Findings

Biogen’s investigational antisense oligonucleotide (ASO), ‘salanersen,’ has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of Spinal Muscular Atrophy (SMA). This designation was granted based on promising early clinical data demonstrating improved motor function and slowed neurodegeneration in pediatric SMA patients who had not achieved optimal outcomes with existing treatments.

Technical / Clinical Details

Salanersen is an ASO designed to increase the production of functional SMN (Survival Motor Neuron) protein when the SMN1 gene, which causes SMA, is defective. The drug modulates the splicing of the SMN2 gene to promote the production of full-length SMN protein. The BTD was granted based on interim data from an exploratory clinical trial in pediatric SMA patients for whom existing treatments provided insufficient benefit. This data showed significant improvements in motor function assessment scales (e.g., Hammersmith Functional Motor Scale-Expanded [HFMSE] score) in patients treated with salanersen compared to the placebo group. Biomarkers of neurodegeneration also decreased, suggesting a deceleration of disease progression. Furthermore, salanersen potentially offers high efficacy with once-yearly intrathecal administration, which is expected to significantly reduce the burden on patients and caregivers compared to the multiple dosing of existing SMA treatment, Spinraza (nusinersen).

Background & Context

Spinal Muscular Atrophy (SMA) is a severe genetic neuromuscular disorder characterized by the loss of motor neurons, leading to muscle weakness and atrophy, often resulting in death in infancy or early childhood if untreated. While groundbreaking SMA treatments like nusinersen, onasemnogene abeparvovec, and risdiplam have emerged in recent years, challenges remain, including suboptimal efficacy in some patients or high administration frequency. The BTD for salanersen represents a significant advancement in addressing these unmet medical needs and further expanding SMA treatment options.

Strategic Significance & Outlook

The Breakthrough Therapy Designation is expected to accelerate the development and review of salanersen. Biogen will work closely with the FDA to rapidly advance its future clinical development program. If salanersen ultimately receives approval, its convenience of once-yearly administration and applicability to patients who have not responded optimally to existing therapies could significantly impact the SMA treatment landscape. This raises expectations for further advancements in ASO technology and the provision of effective therapies for intractable neurological disorders.